Trovagene (TROV) Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in AML

  • Summary:


    Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

    Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicineâ„¢ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including leukemia, prostate and colorectal, today announced new in-vitro and in-vivo data suggesting that onvansertib may provide a new therapeutic option for patients who develop resistance to frontline treatment with venetoclax.

    The data show that onvansertib, as a single agent, inhibits tumor growth in venetoclax (Venclexta® - Abbvie) resistant in-vitro and in-vivo models. Additionally, the data also demonstrate synergy with the combination of onvansertib and venetoclax, providing further support for t ...



    Read Full News:

Log in to reply